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Statement of Translational Relevance:  
Validated biomarkers of prognosis and response to sorafenib have not yet been identified in 
patients with advanced HCC. We assessed whether baseline concentrations of 15 plasma 
biomarkers and various combinations of these biomarkers, as well as mutations in 19 
oncogenes, could predict prognosis or treatment response in patients with advanced HCC 
enrolled in SEARCH, a phase 3 trial of sorafenib with or without erlotinib. We found that high 
baseline plasma HGF and VEGF-A correlated significantly with shorter OS, , and high KIT with 
longer OS. In addition, high VEGF-C correlated significantly with better TTP and DCR. Two 
multimarker signatures, one consisting of 2 markers (HGF and VEGF-A) and the other of 5 
markers (HGF, VEGF-A, KIT, VEGF-C, and epigen), showed significant correlations with OS. 
These findings, if confirmed, could potentially guide clinicians on how to predict patient 
prognosis or response to treatment.  
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ABSTRACT  
Purpose: Sorafenib is the current standard therapy for advanced HCC, but validated 
biomarkers predicting clinical outcomes are lacking. This study aimed to identify biomarkers 
predicting prognosis and/or response to sorafenib, with or without erlotinib, in HCC patients from 
the phase 3 SEARCH trial. 
Experimental Design: 720 patients were randomized to receive oral sorafenib 400 mg BID plus 
erlotinib 150 mg QD or placebo. Fifteen growth factors relevant to the treatment regimen and/or 
to HCC were measured in baseline plasma samples.  
Results: Baseline plasma biomarkers were measured in 494 (69%) patients (sorafenib plus 
erlotinib, n=243; sorafenib plus placebo, n=251). Treatment arm–independent analyses showed 
that elevated HGF (HR, 1.687 [high vs low expression]; endpoint multiplicity adjusted [e-adj] 
P=0.0001) and elevated plasma VEGF-A (HR, 1.386; e-adj P=0..0377) were significantly 
associated with poor OS in multivariate analyses, and low plasma KIT (HR, 0.75 [high vs low]; 
P=0.0233; e-adj P=0.2793) tended to correlate with poorer OS. High plasma VEGF-C 
independently correlated with longer TTP (HR, 0.633; e-adj P=0.0010) and trended toward 
associating with improved disease control rate (univariate:OR, 2.047; P=0.030; e-adj P=0.420). 
In 67% of evaluable patients (339/494), a multimarker signature of HGF, VEGF-A, KIT, epigen, 
and VEGF-C correlated with improved median OS in multivariate analysis (HR, 0.150; 
P<0.00001). No biomarker predicted efficacy from erlotinib.  
Conclusions: Baseline plasma HGF, VEGF-A, KIT, and VEGF-C correlated with clinical 
outcomes in HCC patients treated with sorafenib with or without erlotinib. These biomarkers 
plus epigen constituted a multimarker signature for improved OS.  
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INTRODUCTION 
Hepatocellular carcinoma (HCC) is the second most frequent cause of cancer deaths 
worldwide.(1) Most patients are diagnosed with advanced stage disease, when curative 
treatments, including resection, liver transplantation, and ablation, are no longer an option.(2,3) 
The oral multikinase inhibitor sorafenib, which targets Raf-1, VEGFR1-3, PDGFR, KIT, RET, 
and other tyrosine kinases, has both antiproliferative and antiangiogenic effects.(4) Sorafenib 
has demonstrated survival benefits in patients with advanced unresectable HCC and remains 
the standard of care for this disease based on two phase 3 trials.(5,6) 
Erlotinib is a potent, orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine 
kinase approved to treat patients with advanced non–small-cell lung and pancreatic cancers.(7-
9) In two single-arm phase 2 trials, erlotinib showed modest prolonged progression-free survival 
and promising disease control in patients with unresectable HCC.(10,11) Moreover, a phase 2 
trial of the combination of erlotinib and the antiangiogenic monoclonal antibody bevacizumab, 
which binds to and inhibits vascular endothelial growth factor (VEGF), found that this 
combination led to clinically meaningful progression-free survival and response rates in patients 
with advanced HCC.(12)  
Based on these findings, the SEARCH trial was designed to compare the efficacy and safety of 
sorafenib plus erlotinib with sorafenib plus placebo as first-line treatment in patients with 
advanced/unresectable HCC.(13) In this trial, 720 patients were randomized to sorafenib plus 
erlotinib (n=362) or sorafenib plus placebo (n=358), with a primary endpoint of overall survival 
(OS).(13) The trial did not meet the primary endpoint; median OS was similar in the sorafenib 
plus erlotinib and sorafenib plus placebo groups (hazard ratio [HR], 0.929; P=0.204; 9.5 vs 8.5 
months, respectively), as was median time to progression (TTP; HR, 1.135; P=0.091; 3.2 vs 4.0 
months).(13) Of note, the overall response rate (ORR) with sorafenib plus erlotinib was almost 
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twice as high as the ORR with sorafenib plus placebo (7% vs 4%).(13) In contrast, the disease 
control rate (DCR) was significantly lower (43.9% vs 52.5%, P=0.010) in the sorafenib plus 
erlotinib group compared with sorafenib plus placebo, perhaps due to the shorter treatment 
duration in the sorafenib plus erlotinib group.(13) 
Despite this trial not demonstrating a benefit for the addition of erlotinib to sorafenib, much can 
be learned by assessing biomarkers that may predict prognosis and/or benefit from treatment. A 
previous prospective study demonstrated that lower baseline plasma levels of insulin-like growth 
factor-1 and higher plasma VEGF levels correlated with advanced clinicopathologic parameters 
and poor OS in patients with HCC.(14) In addition, an analysis of the 602 patients in the phase 
3 Sorafenib HCC Assessment Randomized Protocol (SHARP) trial randomized to receive oral 
sorafenib or placebo found that baseline plasma concentrations of angiopoietin 2 and VEGF-A 
were independent prognostic predictors of patient survival in the entire patient population and 
the placebo cohort.(15) Also in SHARP, trends toward enhanced survival benefit from sorafenib 
treatment were seen in patients with high plasma KIT and/or low hepatocyte growth factor 
(HGF) concentrations at baseline (P of interaction = 0.081 and 0.073, respectively). The goal of 
the present exploratory biomarker analysis of patients in SEARCH was to identify biomarkers 
that may predict prognosis and/or benefit from sorafenib, with or without erlotinib, in patients 
with advanced HCC. In this biomarker study 15 candidate mechanistic plasma biomarkers – 
proteins with known or hypothesized relevance to sorafenib’s and/or erlotinib’s mechanism of 
action or to HCC outcome – were examined.  Analytes selected for plasma biomarker analysis 
are either molecular targets of sorafenib or ligands of those targeted receptors (VEGF-A, VEGF-
C, soluble KIT, and PDGF-BB), or are ligands of the EGFR targeted by erlotinib (amphiregulin, 
betacellulin, EGF, epigen, epiregulin, heregulin, heparin binding EGF (hbEGF), and TGF-α), or 
have been implicated in the pathogenesis of HCC and were found to correlate with measures of 
outcome in SHARP (bFGF, IGF-2, and HGF).(15) In addition, the mutational status of 19 genes 
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was analyzed in available tumor samples; the hotspot mutation panel utilized includes genes 
targeted by sorafenib and erlotinib as well as genes reported to be mutated in HCC (16), though 
most at low prevalence. 
 
PATIENTS AND METHODS 
Patients and Samples 
The SEARCH trial has been described in detail.(13) Eligible patients with histologically or 
radiologically confirmed advanced/metastatic HCC not amenable to local therapies, an Eastern 
Cooperative Oncology Group (ECOG) status of 0 or 1, and Child-Pugh class A (determined 
during screening; n=720) were randomized to treatment with sorafenib 400 mg twice daily plus 
either erlotinib 150 mg once daily (n=362) or matching placebo (n=358), stratified by ECOG 
performance score (0 vs 1), macrovascular invasion and/or extrahepatic spread (yes vs no), 
smoking status (current vs former vs never), and geographic region (North America/South 
America vs Europe/South Africa vs Asia-Pacific). The primary endpoint was OS. Secondary 
endpoints included TTP by independent radiologic review, DCR, ORR, and safety.  
Blood samples were collected before treatment (during screening or predose on day 1 of cycle 
1) into tubes containing ethylenediamine tetraacetic acid as anticoagulant. Plasma was 
prepared by centrifugation and removed to a separate tube. The tubes were stored at –70°C 
(although storage at –20°C was acceptable if no –70°C freezer was available) and shipped on 
dry ice every 6 weeks (4–5 weeks if stored at –20°C) to the central laboratory.  
Formalin-fixed paraffin-embedded archival tumor biopsy samples or unstained slides were 
collected at screening. 
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Submission of biomarker samples and consent for tumor genetics were optional per the 
SEARCH protocol; all plasma samples received were assayed for plasma biomarkers, and all 
usable tumor samples received from patients who gave genetic consent were assayed for tumor 
mutations. 
Biomarker Assays  
Candidate plasma biomarkers were chosen based on their known or hypothesized relevance to 
the mechanisms of action of sorafenib and/or erlotinib and/or their relevance to HCC, and the 
planned analyses were prespecified at study design.(15) All plasma biomarkers were measured 
by AssayGate Laboratories (Ijamsville, MD, USA). Plasma concentrations of VEGF-C, 
heregulin, soluble KIT (R&D Systems, Minneapolis, MN, USA), epigen (USCN Life Science Inc, 
Wuhan City, China), and IGF2 (Mediagnost GmbH, Reutlingen, Germany) were measured by 
commercially available enzyme-linked immunosorbent assay kits; and plasma concentrations of 
VEGF-A, HGF, amphiregulin, betacellulin, EGF, epiregulin, HbEGF, TGF-α, bFGF, and PDGF-
BB were measured using multiplex Luminex bead assays (Thermo Fisher Scientific Inc., 
Waltham, MA USA), according to the manufacturer’s instructions. Mutations in 19 oncogenes 
(ABL1, AKT1, AKT2, BRAF, CDK4, EGFR, ERBB2, FGFR1, FGFR3, FLT3, HRAS, JAK-2,  KIT, 
KRAS, MET, NRAS, PDGFA, PIK3CA, RET) were analyzed in tumor DNA by Quintiles 
Laboratories (Marietta, GA, USA) using the Sequenom OncoCarta 1.0 multiplex assay system, 
according to the manufacturer’s instructions (the list of mutations assayed is shown in 
Supplementary Figure 2). All personnel associated with the laboratories performing the assays 
were blinded to treatment group assignments and all clinical data, including outcome. 
Statistical Methods and Analyses 
Statistical analyses were performed using SAS and R software version 9.2 (SAS Institute Inc, 
Riyadh, Saudi Arabia). Clinical outcome measures included in the biomarker analyses were OS, 
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TTP, and DCR. Each biomarker was analyzed as a continuous variable and a dichotomized 
variable (dichotomized using the median and an optimized cutoff point determined using the 
maximum chi-square method, which tests all possible cutoff points between the 25th and 75th 
percentiles and selects the optimal cutoff value), as well as being included in multimarker 
models.  
For multimarker models, feature selection methods were used to identify a subset of biomarkers 
to be used in developing multimarker signatures associated with clinical outcomes.(17) The 14 
plasma biomarkers tested on a continuous scale (excluding Heregulin, for which a large 
proportion of values were BLQ) were included in feature selection and were analyzed as log2 
transformed continuous variables, utilizing a model adjusting for treatment. Penalized Cox 
regression using a bootstrap elastic net (BELNET) was used to investigate the stability of 
feature selection. This procedure repeatedly performs feature selection on bootstrap samples 
(n=50) drawn from the observed data to calculate a selection probability for each feature (ie, the 
proportion of times each of the 14 biomarkers was selected across all bootstrap samples). 
Selection probability thresholds of 0.9 and 0.8 were considered to identify sets of features of 
interest. A composite score was generated using the selected biomarkers from each analysis, 
and optimal cutoffs were identified using the maximum chi-square method.  
For each biomarker associated with prognosis (including both single biomarkers and 
multimarker signatures), multivariable analyses were performed which included clinical variables 
identified as associated with prognosis. Cox regression models were used to identify the clinical 
variables prognostic for OS, TTP and DCR in HCC. The clinical variables tested for prognostic 
significance were as follows: age, ECOG PS, gender, geographic region, race, stage at 
randomization, ascites, macroscopic vascular invasion, extrahepatic spread, cirrhosis, smoking 
status, Child-Pugh score, BCLC score, hepatitis B and hepatitis C. Multivariable models were 
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then run which included the biomarkers of interest and the identified prognostic clinical 
covariates. 
 
RESULTS 
Populations of Patients Evaluated for Biomarkers 
A total of 720 patients were randomized in the SEARCH trial, 362 to sorafenib plus erlotinib and 
358 to sorafenib plus placebo.(13) Plasma samples were obtained from 494 patients (68.6%) at 
baseline, 243 (67.1%) in the sorafenib plus erlotinib group and 251 (70.1%) in the sorafenib plus 
placebo group. Baseline demographic and disease characteristics of patients in the biomarker 
subpopulations were similar to those in the overall SEARCH population (Table 1). Clinical 
outcomes were also similar in the SEARCH biomarker and SEARCH overall populations. In the 
biomarker population, OS in the sorafenib plus erlotinib and in the sorafenib plus placebo 
groups was 9.7 and 8.9 months, respectively (HR, 0.922; 95% CI, 0.749–1.133), and TTP was 
3.2 and 3.9 months (HR, 1.166; 95% CI, 0.937–1.450). In the overall SEARCH population, OS 
of the sorafenib plus erlotinib and sorafenib plus placebo groups was 9.5 and 8.5 months (HR, 
0.929; 95% CI, 0.781–1.106), respectively, and TTP was 3.2 and 4.0 months (HR, 1.135; 95% 
CI, 0.944–1.366; Table 2).  
 
Plasma Biomarkers Correlating With Clinical Outcomes in the Full Biomarker Population 
Median, mean, range, and 25th/75th percentiles are shown for key biomarkers in 
Supplementary Table 3. In the first set of analyses, the treatment arms were combined into 
one group because all patients had been treated with sorafenib, making this a treatment arm–
independent analysis (Table 3). Plasma biomarkers were first assayed for their ability to predict 
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OS. When dichotomized using the maximum chi-square method, high baseline HGF correlated 
significantly with shorter OS (HR, 1.672; 95% CI, 1.352–2.074; max chi-square P=0.00005; 
endpoint multiplicity adjusted [e-adj] P=0.0007; Figure 1A). High baseline HGF also correlated 
significantly with shorter OS when dichotomized at the median (HR, 1.595; 95% CI, 1.294–
1.967; max chi-square P=0.00001; e-adj P=0.0002), when analyzed as a continuous variable 
(HR, 1.148; 95% CI, 1.070–1.233; max chi-square P=0.0001; e-adj P=0.0015; Table 3), as well 
as when analyzed among only those patients with Stage IV disease (HR, 1.708; 95% CI, 1.295–
2.254). High baseline VEGF-A showed a trend toward correlation with shorter OS when 
dichotomized at the optimized cutoff (HR, 1.385; 95% CI, 1.124–1.704; max chi-square P=0.03; 
e-adj P=0.39; Figure 1B), when dichotomized at the median, or analyzed as a continuous 
variable (Table 3), as well as when analyzed among only those patients with Stage IV disease 
(HR, 1.480; 95% CI, 1.126–1.946). High baseline KIT showed a trend toward correlation with 
longer OS (analysis using optimized cutoff: HR, 0.713; 95% CI, 0.562–0.897; max chi-square 
P=0.05; e-adj P=0.60; Figure 1C; analysis as a continuous variable, Table 3). In multivariate 
analyses including known prognostic clinical variables, HGF was independently prognostic for 
OS whether analyzed as a dichotomized (e-adj P=0.0001) or continuous (e-adj P=0.0108) 
variable (Table 3). VEGF-A was also indpendently prognostic for OS (dichotomized, e-adj 
P=0.0377; continuous, e-adj P=0.0457), and both HGF and VEGF-A remained independently 
prognostic when included in the same multivariable model together (Table 3). While the P-
values for the association between KIT and OS in multivariate analyses were 0.0233 and 
0.0323 for dichotomized and continuous analyses, respectively, the adjusted P-values did not 
reach <0.05, and thus this association is not statistically significant. 
 
All plasma biomarkers were also assessed for correlation with other efficacy outcomes (TTP 
and DCR). High baseline VEGF-C correlated with longer TTP when dichotomized using the max 
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chi-square method (HR, 0.615; 95% CI, 0.493–0.767; max chi-square P=0.0003; e-adj 
P=0.0042; Figure 1D), when dichotomized at the median (HR, 0.679; 95% CI, 0.544–0.846; 
max chi-square P=0.0006; e-adj P=0.0078), and when analyzed as a continuous variable (HR, 
0.877; 95% CI, 0.806–0.957; max chi-square P=0.0032; e-adj P=0.0486). High baseline VEGF-
C also correlated with higher DCR when dichotomized at the median (odds ratio, 1.819; 95% CI, 
1.225–2.714; max chi-square P=0.003; e-adj P=0.0421), and showed similar trends when 
dichotomized using an optimized cutoff or when analyzed as a continuous variable. VEGF-C 
remained independently prognostic for TTP in multivariable models when analyzed as either a 
dichotomized (e-adj P=0.0010) or as a continuous (e-adj P=0.0195) variable (Table 3). None of 
the other plasma biomarkers assayed was associated with any efficacy outcome. 
 
Analysis of Plasma Biomarkers as Predictors of Treatment Benefit 
In the second, “predictive” set of analyses, differences in clinical outcome between treatment 
arms were analyzed in biomarker subgroups. Because one arm received sorafenib plus erlotinib 
and the other received sorafenib plus placebo, the biomarker data could be analyzed for 
correlations between biomarkers and erlotinib treatment effect, thus attempting to identify 
biomarkers predicting benefit from one treatment regimen over the other. For example, neither 
patients with low (ie, <195.365 pg/mL) nor high (ie, ≥195.365 pg/mL) baseline betacellulin 
showed significant survival benefit from the addition of erlotinib  to sorafenib treatment 
compared with sorafenib plus placebo (unadjusted interaction P-value=0.357), though a trend 
toward benefit from the addition of erlotinib was seen in the high betacellulin group (HR, 0.725; 
95% CI, 0.522–1.004; P=0.0531) (Figure 2). Likewise, none of the other plasma biomarkers 
showed a significant relationship with treatment effect, suggesting that none of the candidate 
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biomarkers significantly predict benefit from one treatment arm over the other (Supplementary 
Tables 1 and 2, and Supplementary Figure 1). 
 
Multimarker Signatures 
In the third set of analyses, feature-selection methods were used to identify multimarker 
signatures associated with clinical outcomes including generation of a composite score. The 
multimarker signature analysis was performed for both treatment arm–independent and 
predictive analyses. Two biomarkers, HGF and VEGF-A, met the stringent BELNET threshold of 
0.9 in the treatment arm–independent analysis. When patients were divided into those with 
(n=270) and without (n=224) this signature based on a composite score, median OS was 
significantly longer in the former group (11.7 vs 6.8 months; HR, 0.573; 95% CI, 0.465–0.705; 
P<0.00001; Figure 3A). Five markers (KIT, epigen, HGF, VEGF-A, and VEGF-C) met the 
relaxed BELNET threshold of 0.8, with 339 patients with and 155 without the signature. A 
multimarker composite score defined by these 5 markers also showed a statistically significant 
association with OS in treatment arm–independent analysis (11.5 vs 6.0 months; HR, 0.505; 
95% CI, 0.407–0.627; P<0.0001; Figure 3B). Both the 2 marker (HR, 0.050; 95% CI, 0.016–
0.151; P<0.00001) and the 5 marker (HR, 0.150; 95% CI, 0.078–0.287; P<0.00001) sets 
remained independently prognostic of OS in multivariable models including the clinical 
covariates identified as prognostic for OS (see footnote of Table 3). No predictive multimarker 
signature correlating with treatment effect (ie, in a predictive analysis as described above) could 
be identified (data not shown). 
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Mutations in Tumor Samples 
Only 33 tumor samples were evaluable for oncogene mutations. Of these, 30 were negative for 
mutations in the 19 oncogenes assessed. Tumors of 3 patients were positive for gene 
mutations. One patient, with both H-RAS and PDGFRA mutations, was in the sorafenib plus 
erlotinib treatment group and had a best response of stable disease. The second patient, with 
an EGFR T790M mutation, was treated with sorafenib plus erlotinib, and had a best response of 
progressive disease. The third patient had a mutation in MET, although this T992I mutation is at 
best a weak activating mutation and its presence in healthy individuals suggests it may be a 
nononcogenic single-nucleotide polymorphism (18); this patient was in the sorafenib plus 
placebo treatment group and had a best response of progressive disease.  
 
DISCUSSION 
This study, conducted in the setting of the phase 3 SEARCH trial (13), is one of the largest 
studies to date to attempt to identify biomarkers predictive of prognosis and/or treatment benefit 
of erlotinib over placebo in addition to sorafenib in patients with advanced HCC. Of the 720 
patients in the overall SEARCH population, 494 (68.6%) were included in the SEARCH 
biomarker population. Demographic characteristics and clinical outcomes (OS and TTP) were 
similar in the biomarker and overall populations, indicating that the biomarker population was 
representative of the full study population. 
In treatment arm–independent analyses of the SEARCH biomarker population, high baseline 
levels of plasma HGF showed a significant correlation with poorer OS. HGF is the ligand for the 
receptor tyrosine kinase c-MET.  The HGF-MET cascade is associated with 
hepatocarcinogenesis.(19) Elevated HGF levels have been associated with poor prognosis in 
patients with HCC,(15) and high expression of c-MET has been associated with poor outcomes 
Research. 
on May 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR-15-2883 
 15 
 
in patients with HCC treated with sorafenib.(20) The present clinical results, showing that 
elevated HGF levels at baseline were associated with significantly shorter OS in patients with 
advanced HCC, are consistent with these earlier findings. The present study also indicated that 
high KIT levels tended to correlate with better OS.  
Because of the study design, in which both arms were treated with sorafenib, it could not be 
determined whether correlation with outcome in these treatment arm–independent analyses 
was due to a biomarker’s indication of prognosis or due to a biomarker’s correlation with 
sorafenib benefit (or both); such a clear distinction would only be possible to achieve with the 
inclusion of an additional arm without sorafenib treatment. In the phase 3 SHARP trial, high 
HGF (in univariate analysis) and high VEGF-A (in both univariate and multivariate analyses) 
correlated with poor prognosis, whereas KIT was not prognostic.(13) These findings suggest 
that the correlations of HGF and VEGF-A with OS observed in the SEARCH trial were due, at 
least in part, to the prognostic effects of these biomarkers in HCC. In addition, in SHARP, high 
KIT and low HGF showed a trend toward predicting greater benefit from sorafenib treatment, 
whereas VEGF-A was clearly not predictive. These results suggest that in SEARCH, at least 
part of the correlation observed between KIT or HGF and OS in the treatment arm–independent 
analyses may be due to a role in predicting benefit from sorafenib treatment.  
In the present study, in which all patients were treated with sorafenib, high baseline VEGF-A, 
which promotes vascular angiogenesis through activation of endothelial cell associated VEGFR-
1 and VEGFR-2  (21), tended to correlate with poorer OS in univariate analysis and correlated 
significantly in multivariate analysis; since the placebo-controlled SHARP trial showed that 
elevated VEGF-A was prognostic of poor outcome but not predictive of sorafenib benefit, the 
observation in the present study that elevated VEGF-A correlates with shorter survival in the full 
study population (all treated with sorafenib) is consistent with VEGF-A having a prognostic role 
in HCC. In contrast to the VEGF-A results, those with high baseline VEGF-C, a ligand for 
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VEGFR-2 and VEGFR-3 which promotes angiogenesis and lymphangiogenesis (21), had longer 
TTP in the present study, though no similar relationship was observed with OS. Though the 
absence of a non-sorafenib arm in the present study precludes decisive determination of 
whether the VEGF-C result is due to a prognostic effect or is predictive of treatment benefit from 
sorafenib, it has been shown in previous studies that elevated tumor levels of VEGF-C or 
peritumoral levels of VEGF-C in combination with VEGFR-1 and VEGFR-3 correlate with poor 
prognosis in HCC, including shorter disease free survival, time to recurrence, and overall 
survival.(22-24) While these studies examined VEGF-C protein levels in tissue and not in 
circulation, these published findings suggest that VEGF-C, like VEGF-A, is an indicator of poor 
prognosis in HCC. In contrast, a phase 2 study of advanced HCC patients treated with the 
VEGFR inhibitor sunitinib showed that elevated plasma VEGF-C concentrations correlated with 
improved outcomes, including longer TTP and OS and increased DCR (25). This finding in 
combination with the VEGF-C result from the present study suggests that elevated circulating 
VEGF-C levels may enhance the antitumor activity of therapies targeting the VEGFR pathway in 
HCC, though the role of circulating VEGF-C in HCC as compared to tumor or peritumor VEGF-
C is not well studied. In addition, the present study demonstrated that two multimarker 
signatures correlated with OS in treatment arm–independent analyses. One signature included 
two biomarkers, HGF and VEGF-A, and the other included 5 markers, HGF, VEGF-A, KIT, 
VEGF-C, and epigen. 
These biomarkers were also tested in predictive analyses to determine whether their baseline 
concentrations correlated with treatment benefit in one treatment arm versus the other. 
However, none of these biomarkers, either individually or in multimarker analyses, significantly 
predicted differences in benefit from sorafenib plus erlotinib versus sorafenib plus placebo. 
The biomarker analyses in SEARCH were exploratory and hypothesis generating. Although 
several potentially prognostic and predictive biomarkers were identified in the advanced HCC 
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setting, further investigations are needed to confirm and validate their predictive and/or 
prognostic value. 
Acknowledgments  
The authors thank Scott M. Wilhelm and Chetan Lathia of Bayer HealthCare Pharmaceuticals 
(Montville, NJ, USA) for scientific discussion; and BelMed Professional Resources (New 
Rochelle, NY, USA) and C4 MedSolutions, LLC (Yardley, PA, USA), a CHC Group company, for 
editorial support.  
The study was supported by Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, an 
Amgen subsidiary.   
Research. 
on May 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR-15-2883 
 18 
 
REFERENCES 
1. World Health Organization. Cancer Fact Sheet N297. Available at: 
www.who.int/mediacentre/factsheets/fs297/en/. Accessed June 29, 2015. 
2. Thomas MB, Jaffe D, Choti MM, Belghiti J, Curley S, Fong Y, et al. Hepatocellular 
carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials 
Planning Meeting. J Clin Oncol 2010;28:3994-4005. 
3. National Comprehensive Cancer Network. NCCN Guidelines Version 2.2013.  2013. 
4. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43-9006 
exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway 
and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer 
Res 2004;64:7099-109. 
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in 
advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. 
6. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of 
sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: 
a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-
34. 
7. Lee YS, Seo SH, Yang BS, Lee JY. Synthesis and biological evaluation of bis(methoxy 
methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors. 
Arch Pharm (Weinheim) 2005;338:502-5. 
8. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. 
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-
32. 
9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus 
gemcitabine compared with gemcitabine alone in patients with advanced pancreatic 
Research. 
on May 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR-15-2883 
 19 
 
cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. 
J Clin Oncol 2007;25:1960-6. 
10. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, et al. Phase II study of 
Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 
2005;23:6657-63. 
11. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2 study of 
erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-
67. 
12. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E, et al. Phase II trial of the 
combination of bevacizumab and erlotinib in patients who have advanced hepatocellular 
carcinoma. J Clin Oncol 2009;27:843-50. 
13. Zhu AX, Rosmorduc O, Evans TR, Ross PJ, Santoro A, Carrilho FJ, et al. SEARCH: a 
phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in 
patients with advanced hepatocellular carcinoma. J Clin Oncol 2015;33:559-66. 
14. Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and 
prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial 
growth factor in patients with hepatocellular carcinoma. J Clin Oncol 2011;29:3892-9. 
15. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers 
as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin 
Cancer Res 2012;18:2290-300. 
16. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: 
exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids 
Res 2015;43:D805-11. 
17. Li L, Guennel T, Marshall S, Cheung LW. A multi-marker molecular signature approach 
for treatment-specific subgroup identification with survival outcomes. 
Pharmacogenomics J 2014;14:439-45. 
Research. 
on May 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR-15-2883 
 20 
 
18. Tyner JW, Fletcher LB, Wang EQ, Yang WF, Rutenberg-Schoenberg ML, Beadling C, et 
al. MET receptor sequence variants R970C and T992I lack transforming capacity. 
Cancer Res 2010;70:6233-7. 
19. Horiguchi N, Takayama H, Toyoda M, Otsuka T, Fukusato T, Merlino G, et al. 
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine 
activation and enhanced angiogenesis in transgenic mice treated with 
diethylnitrosamine. Oncogene 2002;21:1791-9. 
20. Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, et al. Expression and prognostic 
value of VEGFR-2, PDGFR-beta, and c-Met in advanced hepatocellular carcinoma. J 
Exp Clin Cancer Res 2013;32:16. 
21. Zhan P, Qian Q, Yu LK. Serum VEGF level is associated with the outcome of patients 
with hepatocellular carcinoma: a meta-analysis. Hepatobiliary Surg Nutr 2013;2:209-15. 
22. Yamaguchi R, Yano H, Nakashima O, Akiba J, Nishida N, Kurogi M, et al. Expression of 
vascular endothelial growth factor-C in human hepatocellular carcinoma. J Gastroenterol 
Hepatol 2006;21:152-60. 
23. Xiang Z, Zeng Z, Tang Z, Fan J, Sun H, Wu W, et al. Increased expression of vascular 
endothelial growth factor-C and nuclear CXCR4 in hepatocellular carcinoma is 
correlated with lymph node metastasis and poor outcome. Cancer J 2009;15:519-25. 
24. Zhuang PY, Shen J, Zhu XD, Lu L, Wang L, Tang ZY, et al. Prognostic roles of cross-
talk between peritumoral hepatocytes and stromal cells in hepatocellular carcinoma 
involving peritumoral VEGF-C, VEGFR-1 and VEGFR-3. PLoS ONE 2013;8:e64598. 
25. Harmon CS, DePrimo SE, Raymond E, Cheng AL, Boucher E, Douillard JY, et al. 
Mechanism-related circulating proteins as biomarkers for clinical outcome in patients 
with unresectable hepatocellular carcinoma receiving sunitinib. J Transl Med 
2011;9:120. 
Research. 
on May 26, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on May 24, 2016; DOI: 10.1158/1078-0432.CCR-15-2883 
 21 
 
TABLES 
Table 1. Baseline Patient Characteristics in the Biomarker and Full-Analysis Sets 
 
Biomarker Population Full Analysis Set 
Characteristic Overall 
Sorafenib + 
Placebo 
Sorafenib 
+ 
Erlotinib Overall 
Sorafenib + 
Placebo 
Sorafenib + 
Erlotinib 
n (%) 494 (68.6) 251 (70.1) 243 (67.1) 720 358 362 
Median age, y 61.0 62.0 61.0 — 60.0 60.5 
Sex       
Male 414 (83.8) 210 (83.7) 204 (84.0) 581 (80.7) 286 (79.9) 295 (81.5) 
Female 80 (16.2) 41 (16.3) 39 (16.0) 139 (19.3) 72 (20.1) 67 (18.5) 
Liver cirrhosis 338 (68.4) 176 (70.1) 162 (66.7) 491 (68.2) 251 (70.1) 240 (66.3) 
Ascites 46 (9.3) 23 (9.2) 23 (9.5) 76 (10.6) 36 (10.1) 40 (11.0) 
Macroscopic 
vascular invasion 210 (42.5) 111 (44.2) 99 (40.7) 291 (40.4) 153 (42.7) 138 (38.1) 
Extrahepatic 
spread 290 (58.7) 160 (63.7) 130 (53.5) 424 (58.9) 219 (61.2) 205 (56.6) 
Etiology       
Hepatitis B 159 (32.2) 79 (31.5) 80 (32.9) 255 (35.4) 133 (37.2) 122 (33.7) 
Hepatitis C 130 (26.3) 57 (22.7) 73 (30.0) 191 (26.5) 84 (23.5) 107 (29.6) 
BCLC stage       
B 75 (15.2) 33 (13.1) 42 (17.3) 108 (15.0) 48 (13.4) 60 (16.6) 
C 419 (84.8) 218 (86.9) 201 (82.7) 612 (85.0) 310 (86.6) 302 (83.4) 
Child-Pugh score       
5 353 (71.5) 185 (73.7) 168 (69.1) 498 (69.2) 252 (70.4) 246 (68.0) 
6 128 (25.9) 59 (23.5) 69 (28.4) 203 (28.2) 93 (26.0) 110 (30.4) 
ECOG PS*       
0 307 (62.1) 153 (61.0) 154 (63.4) 439 (61.0) 215 (60.1) 224 (61.9) 
1 184 (37.2) 97 (38.6) 87 (35.8) 278 (38.6) 142 (39.7) 136 (37.6) 
2 1 (0.2) 0 (0.0) 1 (0.4) 1 (0.1) 0 (0.0) 1 (0.3) 
Missing 2 (0.4) 1 (0.4) 1 (0.4) 2 (0.3) 1 (0.3) 1 (0.3) 
Geographic region       
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Americas 88 (17.8) 46 (18.3) 42 (17.3) 173 (24.0) 85 (23.7) 88 (24.3) 
Europe 295 (59.7) 146 (58.2) 149 (61.3) 369 (51.3) 183 (51.1) 186 (51.4) 
Asia-Pacific 111 (22.5) 59 (23.5) 52 (21.4) 178 (24.7) 90 (25.1) 88 (24.3) 
Stage at 
randomization       
I 6 (1.2) 4 (1.6) 2 (0.8) 10 (1.4) 5 (1.4) 5 (1.4) 
II 44 (8.9) 22 (8.8) 22 (9.1) 58 (8.1) 29 (8.1) 29 (8.0) 
IIIA 123 (24.9) 56 (22.3) 67 (27.6) 182 (25.3) 90 (25.1) 92 (25.4) 
IIIB 31 (6.3) 10 (4.0) 21 (8.6) 46 (6.4) 16 (4.5) 30 (8.3) 
IIIC 20 (4.0) 12 (4.8) 8 (3.3) 27 (3.8) 16 (4.5) 11 (3.0) 
IV 269 (54.6) 147 (58.6) 122 (50.2) 396 (55.0) 202 (56.4) 194 (53.6) 
Missing 1 (0.2) 0 (0.0) 1 (0.4) 1 (0.1) 0 (0.0) 1 (0.3) 
Smoking status       
Never 142 (28.7) 71 (28.3) 71 (29.2) 219 (30.4) 107 (29.9) 112 (30.9) 
Former 191 (38.7) 97 (38.6) 94 (38.7) 260 (36.1) 128 (35.8) 132 (36.5) 
Current 161 (32.6) 83 (33.1) 78 (32.1) 241 (33.5) 123 (34.4) 118 (32.6) 
Abbreviations: BCLC = Barcelona Clinic Liver Cancer; ECOG PS=Eastern Cooperative Oncology Group 
performance status. 
All values n (%) except where noted. 
* ECOG PS based on clinical database  
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Table 2.  OS and TTP in the Biomarker Population and Full Analysis Set  
 
 
Abbreviations: HR=hazard ratio; OS=overall survival; TTP=time to progression; ORR=objective response 
rate; DCR=disease control rate; CR=complete response; PR=partial response; SD=stable disease. 
 
 
 
 
 
 
 Biomarker Population Full Analysis Set 
 Sorafenib + 
Placebo 
Sorafenib + 
Erlotinib 
Sorafenib + 
Placebo 
Sorafenib + 
Erlotinib 
OS, months     
Median 8.9 9.7 8.5 9.5 
95% CI 7.4–10.8 8.0–11.0 7.4–10.6 8.2–10.5 
HR 0.922 0.929 
95% CI 0.749–1.133 0.781–1.106 
TTP, months     
Median 3.9 3.2 4.0 3.2 
95% CI 2.9–4.5 2.6–4.1 2.9–4.5 2.7–4.1 
HR 1.166 1.135 
95% CI 0.937–1.450 0.944–1.366 
Best Resonse, %   
ORR (CR+PR) 3.6 6.2 3.9 6.6 
DCR 
(CR+PR+SD) 
51.8 42.4 52.5 43.9 
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Table 3. Summary of Plasma Biomarker Treatment arm–independent Analyses of Interest, Including Both Univariate and Multivariate Analyses 
Marker 
Dichotomized Using Max Chi-Square Analysis Dichotomized at the Median Continuous Variable 
Percentile for 
Dichotomization 
HR  
(95% 
CI) 
Max Chi-
Square 
P Value 
Adjusted
 P Valuea 
HR  
(95% 
CI) 
P Value AdjustedP Valuea 
HR  
(95% 
CI) 
P Value Adjusted P Valuea 
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OS – Univariate analyses 
VEGF-A 57.5 
1.385 
(1.124–
1.704) 
0.0300b 0.3900 
1.280 
(1.040– 
1.575) 
0.0196b 0.2549 
1.172  
(1.045–
1.313) 
0.0070b 0.0976 
VEGF-C 48.4 
0.829 
(0.674– 
1.020) 
0.4000 1.0000 
0.876 
(0.712– 
1.078) 
0.2105 1.0000 
0.973  
(0.900– 
1.054) 
0.5039 1.0000 
HGF 42.9 
1.672 
(1.352–
2.074) 
0.00005b 0.0007b 
1.595 
(1.294– 
1.967) 
0.00001b 0.0002b 
1.148  
(1.070– 
1.233) 
0.0001b 0.0015b 
KIT 68.6 
0.713 
(0.562– 
0.897) 
0.0500b 0.6000 
0.878 
(0.714– 
1.080) 
0.2188 1.0000 
0.756  
(0.607– 
0.941) 
0.0122b 0.1586 
TTP – Univariate analyses 
VEGF-C 48.4 
0.615 
(0.493–
0.767) 
0.0003b 0.0042b 
0.679 
(0.544–
0.846) 
0.0006b 0.0078b 
0.877  
(0.806– 
0.957) 
0.0032b 0.0486b 
DCR – Univariate analyses 
VEGF-C 47.7 
2.047c 
(1.376– 
3.059) 
0.0300b 0.4200 
1.819c 
(1.225– 
2.714) 
0.0030b 0.0421b 
1.251c 
(1.068– 
1.473) 
0.0053b 0.0789 
OS – Multivariate analysesd 
VEGF-A 57.5 
1.386 
(1.119–
1.715) 
0.0029b 0.0377b ND ND ND 
1.196 
(1.061–
1.347) 
0.0035b 0.0457b 
HGF 42.9 
1.687 
(1.340–
2.131) 
<0.00001b 0.0001b ND ND ND 
1.135 
(1.053–
1.225) 
0.0008b 0.0108b 
KIT 68.6 
0.754 
(0.586–
0.963) 
0.0233b 0.2793 ND ND ND 
0.772 
(0.610–
0.978) 
0.0323b 0.3875 
VEGF-A, with 
HGF in model 57.5 
1.419 
(1.144–
1.758) 
0.0014b ND ND ND ND 
1.194 
(1.060–
1.343) 
0.0033b ND 
HGF, with 
VEGF-A in 
model 
42.9 
1.706 
(1.357–
2.151) 
<0.0001b ND ND ND ND 
1.135 
(1.053–
1.224) 
0.0010b ND 
TTP – Multivariate analysese 
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VEGF-C 48.4 
0.633 
(0.505–
0.793) 
0.0001b 0.0010b ND ND ND 
0.864 
(0.791–
0.945) 
0.0014b 0.0195b 
DCR – Multivariate analysesf 
VEGF-C 47.7 
2.156c 
(1.414–
3.309) 
0.0724 1.0000 ND ND ND 
1.183c 
(0.976–
1.137) 
0.0871 1.0000 
Abbreviations: DCR=disease control rate; HR=hazard ratio; HGF=hepatocyte growth factor; OS=overall survival; TTP=time to 
progression; VEGF=vascular endothelial growth factor; ND=not done. 
aEndpoint multiplicity adjusted P value.  
bP<0.05. 
cOdds ratio. 
dOS model included the following clinical covariates identified as prognostic for OS in the SEARCH biomarker population: ECOG PS, stage, 
macroscopic vascular invasion, extrahepatic spread, Child-Pugh status, BCLC score, and hepatitis B, and the individual biomarker unless 
multiple biomarkers noted. 
eTTP model included the following clinical covariates identified as prognostic for TTP in the SEARCH biomarker population: age, gender, 
geographic region, stage, extrahepatic spread, and hepatitis B. 
fDCR model included the following clinical covariates identified as prognostic for DCR in the SEARCH biomarker population: age, stage, 
extrahepatic spread, smoking status, BCLC score, and hepatitis B. 
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FIGURES 
Figure 1. Kaplan-Meier survival curves showing correlations between optimized dichotomization 
thresholds of baseline biomarker concentrations and clinical outcomes in patients in the 
SEARCH trial treated with sorafenib plus placebo or sorafenib plus erlotinib. (A–C) Correlations 
between OS and (A) HGF, (B) VEGF-A and (C) KIT concentrations. (D) Correlation between 
TTP and VEGF-C concentration.  
 
Figure 2. Kaplan-Meier survival curves of treatment effect on OS in patients with low (left panel) 
and high (right panel) baseline betacellulin (max chi-square interaction P=0.357). Betacellulin 
was dichotomized using the max chi-square optimized cutoff. BL=baseline; Erlot=erlotinib; 
Sor=sorafenib. 
 
Figure 3. Kaplan-Meier survival curves of OS in (A) patients with (n=270) and without (n=224) a 
2-marker signature (HGF, VEGF-A) and (B) patients with (n=339) and without (n=155) a 5-
marker signature (HGF, VEGF-A, KIT, epigen, VEGF-C) who were treated with sorafenib plus 
placebo or sorafenib plus erlotinib.  
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